Rallybio (NASDAQ:RLYB) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Rallybio (NASDAQ:RLYB) to a hold rating in a research note issued to investors on Saturday.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Rallybio in a research report on Monday, December 29th. Four research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Reduce”.

Rallybio Stock Performance

Shares of NASDAQ RLYB opened at $8.04 on Friday. The stock has a market cap of $42.53 million, a price-to-earnings ratio of -3.14 and a beta of -1.13. Rallybio has a fifty-two week low of $1.76 and a fifty-two week high of $11.49. The firm’s 50-day simple moving average is $7.03 and its 200 day simple moving average is $5.80.

Rallybio (NASDAQ:RLYB) last issued its quarterly earnings data on Thursday, March 12th. The company reported ($1.03) EPS for the quarter, topping analysts’ consensus estimates of ($1.04) by $0.01. The firm had revenue of $0.22 million during the quarter, compared to analyst estimates of $0.10 million. Rallybio had a negative return on equity of 56.93% and a negative net margin of 1,046.39%. On average, sell-side analysts predict that Rallybio will post -1.34 EPS for the current year.

Institutional Investors Weigh In On Rallybio

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Citadel Advisors LLC lifted its position in shares of Rallybio by 576.1% during the 3rd quarter. Citadel Advisors LLC now owns 438,705 shares of the company’s stock worth $219,000 after buying an additional 373,821 shares in the last quarter. Renaissance Technologies LLC grew its holdings in shares of Rallybio by 16.9% in the fourth quarter. Renaissance Technologies LLC now owns 835,692 shares of the company’s stock valued at $573,000 after acquiring an additional 120,892 shares in the last quarter. Susquehanna International Group LLP grew its holdings in shares of Rallybio by 485.9% in the third quarter. Susquehanna International Group LLP now owns 136,294 shares of the company’s stock valued at $68,000 after acquiring an additional 113,031 shares in the last quarter. XTX Topco Ltd increased its position in shares of Rallybio by 64.6% during the fourth quarter. XTX Topco Ltd now owns 97,313 shares of the company’s stock valued at $67,000 after acquiring an additional 38,205 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in shares of Rallybio by 1.2% during the fourth quarter. Geode Capital Management LLC now owns 248,005 shares of the company’s stock valued at $170,000 after acquiring an additional 2,996 shares during the last quarter. Hedge funds and other institutional investors own 90.34% of the company’s stock.

About Rallybio

Rallybio Therapeutics, Inc (NASDAQ: RLYB) is a clinical‐stage biotechnology company focused on developing and commercializing therapies for people living with rare genetic diseases. The company’s scientific approach leverages diverse modalities—including monoclonal antibodies, small molecules and enzyme replacement—to address high‐unmet‐need conditions in areas such as immunodeficiency, metabolic disorders and dermatologic diseases. Rallybio’s pipeline is designed to advance through registrational clinical trials with the goal of delivering first‐in‐class or best‐in‐class therapies to patients who currently have limited or no approved treatment options.

Among Rallybio’s lead programs is RBX‐100, an investigational therapy for congenital athymia, a rare pediatric immunodeficiency.